drugset / Trial / NCT06835296
A Study of Oral YUQ-A1007 in Healthy Volunteers
RandomizedSequentialOpen-labelTreatment
Summary
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies. This study is first-in-human (FIH) study of YUQ-A1007. The goal of this trial is to evaluate the safety, tolerability, and pharmacokinetics of oral YUQ-A1007.
Timeline
- Start
- 2025-03-20
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YUQ-A1007 | Unknown | 200 mg | Oral |
| Subject | YUQ-A1007 | Unknown | 800 mg | Oral |
| Subject | YUQ-A1007 | Unknown | 1600 mg | Oral |
| Subject | YUQ-A1007 | Unknown | 3200 mg | Oral |
Indications
No indication recorded.